Consolidated Financial Result Briefing
for the fiscal year ended March 31, 2024

CYBERDYNE, Inc.
May 15, 2024

Consolidated financial statements

2

FY2024 - Consolidated Results Summary (IFRS)(Unit : Millions of yen)

FY2022

FY2023+/-

YoY

Revenue

3,289

4,354

+1,065+32.4％

Operating profit-1,145-2,018-873

ーProfit before tax

53-1,141-1,194ーProfit attributable toowners of parent-298-1,476-1,178ー-1,005-1,177-172

ー☆

EBITDA

Revenue

Operating pro t

Pro t before tax

4,354 Million
YoY +1,065 million（+32%）-2,018 Million
YoY -873 Million-1,141 Million
YoY -1,194 Million• Increase from rental outside Japan +121 Million• Increase from treatment service in US RISE Group etc. +361 Million• Increase from acquisition of new business area such as
German mobility company +582 Million• Increase from rental +137 Million• Initial investment in U.S. and European subsidiaries-350 Million• One-time losses due to impairment of good will-660 Million* Operating pro t without this onetime losses-1,358 Million*

YoY -213 Million• Increase of operating loss -873 Million• Finance income/expenses and gain/loss related to CEJ Fund -321 Million(FY23 877M - FY22 1,198M = -321M☆ EBITDA = Operating profit ＋ Depreciation and amortization ± Other income and expenses

fi

fi

fi

3

Consolidated nancial results (IFRS)
Performance trends【Q4 results】Sales +24% (QoQ comparison)
FY2022
Q4(Unit : Millions of Yen)FY2023

Quarter on Quarter

Q1-Q4

Q1

Q2

Q3

Q4

915

1,045

1,058

1,115

1,135

4,354

+20

+1.8%

+220

+24.0%

440

480

480

517

484

1,961

-33

-6.3%

+44

+10.1%

475

566

579

598

651

2,393

+53

+8.8%

+176

+37.0%

R&D Expenses

241

174

180

163

360

877

+197

+120.9%+119+49.6%

Other SG&A

757

766

757

771

958

3,251

+187

+24.3%+201+26.5%

Other income/expenses

127

67

-651

49

252

-282

+203

+411.2%+125+98.4%

Operating profit

-396

-308

-1,008-287-415-2,018

-129

-

-19

-

Finance income/expenses

434

363

-12

-106

-184

61

-78

-

-618

-142.4%

Other

-97

712

74

6

24

816

+18

+121

-

Profit before tax

-59

767

-947

-386

-575

-1,141

-189

-

-516

-

Profit attributable toowner of the parent

-366

330

-933

-349

-525

-1,476

-176

-

-159

-

EBITDA

-488

-212

-194

-177

-595

-1,177

-418

-

-107

-

Revenue
Cost of sales

Gross profit

+/-

+/- %

Year on Year

+272.6%

+/-

+/- %

fi

4

Consolidated nancial results: Revenue/Operating pro t (Margin)
Operating pro t from rental of products 818 Million (Operating pro t margin 46%)

Revenue

Product rental

Operating profit(Margin)

Revenue

Treatment service

Operating profit(Margin)New businessexpansion

Revenue

Operating profit(Margin)☆

☆

☆

(Unit : Millions of Yen)FY2022
Q1-Q4

FY2023
Q1-Q4

+/-

+/- %

1,640

1,762

+121

+7%

744 (45%)818 (46%)

+74

+10%

1,285

1,646

+361

+28%

-310 (-24%)-552 (-34%)

-242

-

364

946

+582

+160%

-161 (-44%)-197 (-21%)

-35

-

☆☆

RD expenses andHead office expenses

Adjusted amount-1,418-2,087-670-

Consolidated total

Revenue

3,289

4,354

+1,065+32%-1,145 (-35%)-2,018 (-46%)

-873

-

(IFRS)☆

Operating profit(Margin)Operating income by business segment is the amount of pro t or loss, which is revenue minus operating expenses, for each business.

☆☆ RD expenses and head of ce expenses, are adjustment amount of R&D expenses, head of ce administrative expenses, other income and expenses, etc.

Without one-time expense of (660M), -1,427M• Rental of product: Rental income from the Group’s product (include income from sold products)• Treatment service: Income from treatment at the Group’s rehabilitation facilities (including Robocare)• New business expansion: Revenue from new business area of the Group (subsidiary company in mobility and sleep apps)

fi

fi

fi

fi

fi

fi

fi

5

Rental revenue by each products
Overseas product rental sales increased by 190M YoY (+30%)
Usage

Product classification

Japan

Outside Japan

Total

HAL Lower Limb Type(Medical)333

517 +40％850

HAL Lower Limb Type(non-medical)

163
(179)

-

163

HAL Single Joint Type

90

100

190

HAL Lumbar Typefor Well-being

114
(162)

95

(113)

209

HAL Lumbar Typefor Labor Support

46
(65)

-

46

Mobility Robot

139
(89)

-

139

Other (Acoustic X and other products)

60

103

164

Total

946

816 +30％

1,762

Cybernics Treatment(Functional improvement/
regeneration)

Care andfor well-being

Labor Support(CL02 etc.)

(325)

(116)

(78)

(1,015)

(369)

(82)

(62)

(626)

(694)

(Unit : Millions of Yen)
Top：FY2023 Q1-Q4(Bottom：FY2022 Q1-Q4)

(179)

(198)

(275)

(65)

(89)

(140)

(1,640)6

Consolidated nancial results (IFRS) by geographical region
Signi cant increase of oversea sale +1,155M (53% to 67% of total revenue)

Japan 33%

1,521M

Americas 34%

1,457M

Americas 35%

1,102M

Japan

47%

APAC 11%

1,547M

468M

EMEA 8%270M

EMEA 21%

370M

908M

APAC 11%
FY2022 Q1-Q4

FY2023 Q1-Q4

Americas: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Paci c * Revenue from Japan is stated separately

fi

fi

fi

7

Ref) Consolidated nancial results (IFRS)
by geographical regions and type of transaction
Signi cant increase in overseas revenue from each type of transaction(Unit : Millions of Yen)FY2023 Q1-Q4

Japan(FY2022 - Q1-Q4)

Americas946 -7％

Rental of products

Treatment service

Total

280 +36％

468 +27％

1,762 +7％(370)

(1,640)

(51)

(205)

137 -19％

1,453 +38％

55 -14％

373

+3％

(364)

Total

+34％

APAC

(1,015)(169)

New businesses

68

EMEA

(1,051)

-

(65)

573
(-)

-

-

1,646 +28％
(1,285)946 +160％(364)

1,457 -6％

1,521 +38％

908 +236％

468 +27％

4,354 +32％

(1,547)(1,102)

(270)

(370)

(3,289)fi

fi

8Outline of the business

9Realization of Techno-peer Support Society
A future society where people and technology coexists, cooperates and mutually support each other
For wide variety of people faced with health, physical function, cognitive and psychological problems
A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives

Social reformation realized by technology

Brain

Technology

Peer

Society
1.0

Society
2.0

Society
3.0

Society
4.0

Future society where people
and technology coexists,
cooperates and mutually
support each otherSociety 5.0/5.1

Technology further promotes healthier lives・・・Hyper-aging society

Physical space

Cyber space

Cybernics Space

Fusion of “Human” and “Cyber/Physical space” using Cybernics Technology!
→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry
10Cybernics Technology: Innovative core technology of Cybernics Industry
Cybernics: Fuses and combines humans, AI-Robots and Information Systems*Cybernics: Science and technology in
cutting-edge areas that combine different fields
such as brain/neuroscience, physiology,
artificial intelligence (AI), robotics, information
technology (IT), psychology, economy andinnovation with a focus on Human, AI-robots
and Information Systems to realize the fusionof bio/medical technologies and AI, robotics
and information technologies.

(Reference)

The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernics
as pioneering cutting-edge innovative science and technology areas

11

Business in the integrated space of “Human” + “Cyber/Physical Space”
Improving the well-being ofseniors and people with disability

HCPS Human Collaborative Robotics

Towards the 5th Industrial Revolutions!
“Human”+”Cyber/Physical Space”

Prevention, early detection andmedical/healthcare

HCPS Fusion Technology
Cybernics Industry
that will follow Robot and IT Industry

HCPS Human Collaborative Robotics

Prevention/Early Detection/Medical&Healthcare

Cybernics Space

Cybernics Space

Fusion of “Human” + “Cyber/Physical Space”

Fusion of “Human” + “Cyber/Physical Space”

Improving well-being of seniors and people with disability

Work support and improving ef ciency
through AI automation

Improving the well-being through supportingand supervising solutions
Improving well-being through supervising and live support solutions

HCPS Human Collaborative Robotics

HCPS Human Collaborative Robotics

Work support and improving ef ciency through AI automation
Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

fi

fi

12

【Medical】Global Dissemination of Cybernics Treatment

CYBERDYNE, Inc.

13

Motion principle of Cybernics Treatment Technology
Wearable Cyborg HAL : Cybernics Treatment that induces functional regeneration
Signals from a person's brain nerve system are processed by signal processing and artificial intelligence inreal-time, HAL moves as if it were a part of the person's own body according to the person's intention

Medical1) HAL obtains information related to the brain nerve and muscles from the peripheral part of the body2) HAL synchronizes with the wearer’s intentions and functions according to the intention
3) Forms an interactive bio-feedback loop to induce improvement in the body-nerve and muscles systems,
achieving the goal of the Cybernics Treatment
14

【Medical】Insurance reimbursement for Cybernics Treatment
Increased insurance points after con rming safety and ef cacy during 5 years of post-marketing surveillance✦Excerpts from the Proposal to Evaluate the Medical Technology (why it should be reevaluated)submitted by the Japanese Society of Neurological Therapeutics – Translated by CYBERDYNE“During 5 years of post-marketing surveillance, the medical technology produced signi cant improvement ofphysical function towards slowly progressive neuromuscular disease, which are intractable diseases with noestablished treatment methods that are effective. The medical effect observed was unheard of by any
existing treatment methods, including pharmaceuticals approved for these diseases. Due to the progressive
nature of these intractable diseases, research on the natural course of the disease suggest a gradual declineof motor functions. However, when this medical technology was utilized repeatedly over a long duration of 3.5
years, an opposite trend was suggested, and motor function was maintained/improved. Furthermore, themedical technology did not increase the destruction of the patient’s muscles. The CK value in the blood**
was actually in the declining trend, which is medically noteworthy. Thus, it was suggested that medical
technology is a safe treatment method for progressive neuromuscular patients. The medical technology
should no longer be regarded as a treatment method to support gait exercises. It should be reevaluated as a
new treatment method to activate the loop of the patient’s brain-nerve systems.”
Added to items not covered by the DPC comprehensive evaluation (items calculated at piece rate)!
Increased reimbursement points (40,000 yen for the rst 9 sessions and 20,000 yen for the following sessions) are realized!

fi

fi

fi

fi

15

【Medical】Cybernics Treatment (functional improvement/rehabilitation treatment)
Cybernics Treatment: Developed as innovative method utilizing HAL for treating brain-nerve-musculoskeletal disorders

HAL Lumbar TypeHAL Single Joint Type

HAL Lower Limb Type*The treatment services operated by the Group are classi ed as “service sales” and “rental sales” in cases where products are rented based on rental contractfi

16Global dissemination of Cybernics and reinforcing collaboration ①

INTERNATIONAL CONFERENCE on CYBERNICS HAL 2023
2023.10.13 Kuala Lumpur Malaysia

Strengthening international collaboration by bringing together clinicians, researchers,
and other experts from around the world who work with Cybernics
17

Global dissemination of Cybernics and reinforcing collaboration ②
2024.1.12 Hannover Germany

Cybernics & Neurobionics Summit 2024 (Jointly hosted by International Neuroscience Institute)
Gathering the world's leading pioneers in cutting-edge developments in Cybernics and neurobionics

Joint hosts
Dr. Madjid Samii (center) - Founder of INI, President of INI
Dr. Amir Samii (right) - Vice President of INI
18

Progress of approval by the U.S. FDA
US FDA becomes to rst to clear HAL Small Model and Cerebral Palsy (2024/5/7)*Above 12 years old

Use image of HAL Small Model*

Applicable height
150〜190cm
Applicable height
100〜150cm

Small
Model

Conventional
model*Product used in this image differs from the medical version© Okayama Robocare Centerfi

19Development pipeline (1)１）Medical HAL (Lower Limb Type) : Clinical trials etc.
Target disease

Product
Development

Clinical Trial(Exploratory)

Neuromuscular Disease(8 types of disease such as
ALS and muscular dystrophy)

Clinical Trial(Validation)

Application/
examination

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance

As of May 15 2024

Current status

2023/10MHLW approves insurance reimbursement
・HTLV-1 Associated Myelopathy (HAM)

FY2022 revision (DPC calculation)

・Hereditary spastic paraplegia

Planning for insurance reimbursement

Planning for public health insurance

Public health insurance approved

Spinal related disease

Applying for expansion of target diseases(2 diseases virus and hereditary)

Spinal Cord Injury

Obtained medical device clearance
Public workers
Compensation
insurance (Germany)

2024/5 !!
US FDA clears three additional diseases
・Cerebral Palsy*

Stroke・HTLV-1 Associated Myelopathy (HAM)
・Hereditary Spastic Paraplegia

Cerebral Palsy

Communicating with regulators
Preparing trial towards public healthinsurance (Germany)
Planning for insurance reimbursement
Preparing for additional clinical trial
Planning for public health insurance
Planning for insurance reimbursement
Investigator-initiated clinical trial*Above 12 years old

Multiple Sclerosis

20

Development pipeline (2)２）Medical HAL (Lumbar Type)：Clinical trials etc.
Target disease

Product
Development

Clinical Trial(Exploratory)

Clinical Trial(Validation)

Application/
examination

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance

Parkinsons
DiseaseAs of May 15 2024

Current status

Currently designing a protocol forclinical trials while con rming
ef cacy through pilot studies*Topics : Started working on parkinsons disease, a disease with over nine million patients world wide３）Medical HAL (Single Joint Type)
Target disease

Brain-nerve（e.g. stroke)

Orthopedics（e.g.Post knee joint replacement)

Product
Development

Clinical Trial(Exploratory)

Clinical Trial(Validation)

Application/
examination

As of May 15 2024
Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance
PublicHealth Insurance

Current status
Equipment for increasing exercise load
Planning for insurance reimbursement
Planning for insurance reimbursement
Planning for insurance reimbursement
Planning for insurance reimbursement
Planning for insurance reimbursement

fi

fi

21

Medical device approval for Medical HAL Lower Limb Type

Expansion of cleared diseases in USA (Disease/Size)
As of May 15, 2024

Japan
USA

(Preparing for additional
trial)(Communicating withregulators)

Neuromuscular Disease*

Other diseases

Small size

Approved

・HTLV-1 Associated Myelopathy (HAM)
・Hereditary spastic paraplegia(application in progress)

・Cerebral palsy
・HTLV-1 Associated Myelopathy (HAM)
・Hereditary spastic paraplegia

Approved

Approved

Approved

India

Approved
Approved
Approved
Approved
Approved
Approved
Approved
Approved

Approved
Approved
Approved
Approved
Approved
Approved
Approved
Approved

Taiwan(application in progress)

Australia

Approved

Approved
Approved
Approved
Approved
Approved
Approved
Approved
Approved
Approved
Approved

Türkiye
Saudi Arabia
Malaysia
Indonesia
ThailandAPAC

Spinal Cord Injury

Approved

EuropeEMEA

StrokeSingapore(application in progress)(application in progress)

Approved*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

22

Global dissemination of Medical HAL/Cybernics Treatment

Available in over 20 countries and regions
Cyberdyne Care Robotics(Germany）

CYBERDYNE
HQBrooks Rehabilitation(US Florida）

EMEA Base
Cyberdyne Care
Robotics GmbH
(Germany)

Americas BaseRISE Healthcare Group（USA California）

CYBERDYNE
USA INC.

PERKESO ‒ REHABILITATIONCENTRE MELALA(Malaysia）
Coopselios(Italy）

APAC BaseSingapore General Hospital(Singapore）

CYBERDYNE
MALAYSIA
SDN. BHD.
EMEA : Europe, Middle East and Africa
23Social implementation of Cybernics Treatment (USA)Development of Cybernics Treatment through Rise Healthcare✦ Strong business in LA・San Diego✦ Commenced fee-based service from 2023
(out-of-pocket+insurance hybrid treatment)✦ No. treatment sessions increased 2.4 times,
even though fee-based service started*✦ Top3 users are stroke, Parkinson’s disease
and spinal cord injury patients✦ 76% referred by doctors/patient-to-patient/patient associations*Performance from January to December

Accelerate business further in light of approval of HAL small model,
and expansion of indications for cerebral palsy, etc.
24Social implementation of Cybernics Treatment (Malaysia)
Collaboration with Malaysian government-af liated organizations to promote Cybernics Treatment
2019.8 Strengthening ties with the Malaysian government
Business alliance with PERKESO

2022.2

Established Malaysian subsidiaryCYBERDYNE MALAYSIA SDN. BHD.

HAL rented units
As of March 2024
114 units

2018.11End of 2024(schedule)
Completion of
PERKESO National NeuroRobotis and Cybernics
Centre106

Social Security Organization(PERKESO) started utilization of HAL

92
72

2019.52022.6Opened APAC's rst Cybernics Treatment Center

FY18

FY19

FY20

FY21

PERKESO announces construction of
PERKESO National Neuro-Robotis andCybernics Centre

FY22

FY23

FY24

fi

fi

25

Social implementation of Cybernics Treatment (Malaysia)
Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance
SOCSO/PERKESO (Malaysia Public Social Security Organization)
SOCSO has four functions: disability pension, survivor’s pension, medical coverage and occupational injury coverage, and is compulsory for
Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral bene ts,
child support and nursing care bene ts for illness or injury that occurs while commuting to and from work.

Facilities with HAL (12 facilities)
人的資源省大臣は、SOCSOリハセンターの

KESUMA Minister Urges Nationwide Expansion of
全国的な拡大を要請
SOCSO
Rehabilitation Centers

SOCSO Rehabilitation Center

https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres- ve-years-454129

fi

fi

fi

26

Social implementation of Cybernics Treatment (Malaysia)
The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia
PERKESO National Neuro-Robotic andCybernics Centre✓ Construction underway in Ipoh, Perak,
Northern part of Malaysia(Scheduled by the end of 2024)✓ First phase project✓ 15.6 Hectare (Approx. 3.4 baseball stadiums)✓ Gross oor area is approximately 86,400
square meters✓ Capable of accommodating 700 patients at any
given time

Strategic base for social implementation ofCybernics Industry, such as HAL, Cybernics
Products and technologies of other companies
that CYBERDYNE invests through C-Startup
https://www.perkeso.gov.my/images/kenyataan̲media/2023/190203̲̲LAWATAN̲MENTERI̲SUMBER̲MANUSIA̲KE̲TAPAK̲PUSAT̲REHABILITASI̲PERKESO̲PERAK.pdf?
TSPD̲101̲R0=08e2dacd5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e
10251d84d1723291abc11ccb8adc c6ab4640a6f84d8e56752b87e7c10ac4d5baf7b

ff

fl

27

Spinal Cord Injury: Clinical Trials by German Insurance Authorities
Clinical trials to be conducted on the premise of German public medical insurance coverage
G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage
G-BA approves Cybernics Treatment as the standard of care to be considered for spinal cord injury patients (in accordance with §137eSGB V of the Study Regulations)
G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by public health insurance for Cybernics Treatment in advance).
The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Protocol for Clinical Trials
2023/01 Protocol outline presented
2023/03 Expert hearing held
2023/09 Protocol guideline announced→ Commenced selection of CRO on March 2024

G-BA (Federal Joint Committee): Organization at the federal level that determines basic bene ts, prices, standards, etc. for German insurance treatment.
§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes nal evaluations of promising treatments that
could become the standard of care.

fi

fi

28

Social implementation of Cybernics Treatment (Italy)
Promoting “Scienti c Evidence-Based Rehabilitation Model”
Utilizing 25 units of HAL for treatment of approximately 1,000 stroke and spinal cord injury patients

Key points of collaboration✦ Operates Italian Cybernic Center - Second walk(Within Italy)✓Social cooperative association established on 1984
✓Service in medical, care and education elds
✓Provides service to approximately 6,500 people daily in 8 areas of Italy✓Over 3,000 professionals✦ Cooperation for public health insurance
reimbursement in Italy✦ Utilization of Coopselios Network in Asia,
Middle East, South America and Africa

fi

fi

29

Healthcare and labor support

CYBERDYNE, Inc.

30

【Healthcare】Neuro HALFIT (Functional Improvement Program)
Program to improve brain-nerve-musculoskeltal function at Robocare Center

HAL Lumbar TypeHAL Single Joint Type

HAL Lower Limb Type31

Medical Healthcare Service for Individuals:Neuro HALFIT at Home
Expansion of remote services connecting home and hospitals/facilities through cloud computing【Integrated Cybernics System】

House（つーざー）

LTE/5G［Cloud］

Physical information

Physical information(User)

User authentication
Device authentication
Data baseSupportCybernics Device

Monitor tablet

Induceimprovement ofbrain-nerve andphysicalfunction

LTE/5G

Remote service to counter the pandemic

Physicalinformation

PhysicalinformationHouse（つーざー）(User)
SupportInduceimprovement ofbrain-nerve andphysicalfunction

Monitor tablet

Cybernics Device

SupportSupportFacility（つーざー）(professional)

Physical information

Physical information
SupportSupport

Robocare Center

Monitor tablet

Monitor tablet

Robocare Center（CYBERDYNE）（CYBERDYNE）
Professional
Staff

32

Robocare Center: Nationwide expansion of Neuro HALFIT
Expansion of hubs in the medical healthcare service business for individuals

Available in 18 locations
nationwide33

【Healthcare】HAL Lumbar Type care prevention program
Signi cant improvement in mobility functions (daily activities such as standing, walking, running, sitting) of the elderly

Care prevention program (Kanagawa Mirai MIBYO Cohort Study)
Interim evaluation results of short-term intervention twice a week for a total of 10 sessions

Evaluation item

Before HAL

After HAL

Mean

Mean

Improvement rate

P-value

1.05（0.98, 1.12)

1.43（1.35, 1.51)

36%<0.001***

8.5

4.4

93%

<0.001***(95%CI)

10m walk (walking speed m/sec)

Locomotiv 5 check*Signs of motor unit deterioration(7.7, 9.3)

(95%CI)(3.3, 5.4)

Recruited N=80 people Out of which, Participants N=79, (Average 75yo, : Intervention group 40 (one drop-out) , Control group 39 (one drop out)
Research and development of nursing care prevention programs utilizing healthcare robots
fi

34

※

※

【Healthcare】Neuro HALFIT at Home (for individuals in daily lives)

Functional improvement program at home (expands home visit services)

Use image of Neuro HALFIT at Home

HAL is data-linked with the Cyberdyne Cloud, which visualizes biopotential signals that command body
movements and posture information, etc. This system enables the wearer to obtain visual feedback andallows the trains to customize a program for each user based on the results of data analysis*The Home programs are classi ed as “service sales” and “rental sales” in cases where products are rented based on rental contractfi

35

【Labor Support】HAL Lumbar TypeNew HAL Lumbar will be announced soon, making the device light weighted and thinnerLightest• Can be worn for long hours
Active type device • Became even lighter (2.7kg)
Slim design(back free)
Assist walkLighter！
Thinner！

• Can be worn together with safety belts(full body) and air-conditioned clothes
Can drive cars while wearing it•• Can move smoothly tothe required venue

Can move around in
crouching posture

New

Current• Assists various practical movements
Construction sites,

IoH/IoT device• Visualize workload analysis and operating status! airports, and distribution
integrated production management

Integrated
Cybernics Systemwarehouses etc.

It moves according to the•
Wearable Cyborg
wearer's intention
Puts on in 10 seconds

Water/dustproof(IEC reg IP54)• Easy to put on and take off, share withmultiple people!

• Can be worn outdoors, even in the rain!
(New model is also waterproof)

Labor
manager36

【Workplace】Disinfection/Cleaning Robot CL02
Make of ce buildings smarter and reduce management costs with advanced technology
Can also be linked with building OS! (Also considering collaboration with major industry players)•••

Extensive
Cleaning ability•
Can be used for •multiple tasks such•as disinfection•••

Visualizes
assigned tasks

High-speed autonomous navigation (Can safely clean at 4km/h to cover massive space in a short time
Massive cleaning area (Detects wall that is 30m away and covers max 3,000m2 with full charge battery)High vacuum performance (One of the best in the industry)

Disinfection agent sprayer (Disinfects handrails and benches)
UV Ray Disinfector (Set on the bottom of the robot to disinfect oors)
Wiper cleaner (Small sound as it does not use vacuum)
Carpet spray & Brushing (Make carpet long lasting)

Dust distribution map (visualizes result of the task)
Navigated route (to create ef cient and effective cleaning plan)

Airports, oce buildings,

CYCLES(Cloud for CL02)

Integrated
Cybernics Systemfacilities, shopping
centers etc.

•

Automatically rides
on the elevator•

Elevator interface unit developed inhouse(Can connect to elevators developed by multiple vendors)
Can work on multiple oors (Expands the space that can be cleaned)

Human
•
•

Cloud linkage“CYCLES” designed for the Robot (realizes high usability and management)
Integration with the base system

Information transfer
and remote control

fl

fi

fl

fi

ffi

37

Strategy for growth

CYBERDYNE, Inc.

38

Image of growth scenario: Strengthen development areas and business strategies

Towards gradual growth
Strengthening cloud computing,personalized business, M&A, etc.

(evolution of the business model, M&A)

Expanding existing businessNow(expanding usage, business towards
individual users, etc.)

Developing the business base(Expanding product lineup, obtaining
regulatory approvals in eachcountries)

Time
39
fi

Businessscale

Reinforcing existing business,pioneering new eld

HCPS fusion technology：Cybernics/Human cooperative robotics
As a commitment to science, technology and innovation, CYBERDYNE
participated in the Cabinet Of ce Strategic Innovation Creation Program (SIP) to strengthen growth strategies

Human

HCPS fusion human cooperative robotics
fusion of “Human” + “Cyber/Physical Space”
AI
Robot

1)
2)
3)
4)

AI
Information

Application to various living spaces such as houses, facilities, workplaces, etc.
Utilization of HCPS fusion master/remote control technology (Cybernic master/remote technology) integrated with human information (physiology, body, behavioral
cognition, psychology, etc.)
Non-invasive acquisition and utilization of human information through HCPS fusion human collaborative robotics
Linking with other related technologies to improve the independence and freedom of seniors and people with mobility problems

fifi

Source: Cabinet Strategic Innovation Program (SIP), Secretariat of Science, Technology and Innovation, Cabinet Of ce, Government of Japan, “Development of Fundamental Technologies and Rules for Expanding Human-Coordinated Robotics: Strategy and R&D Plan for Social Implementation,” Pg 5.

40

Future of medical healthcare and healthy life
Prevention/pre-symptomatic, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life
Pre-Hospital

Hospital

Early medical・life period Prevent/pre-symptomatic

Diagnose, treat, inpatient/outpatientearly medical・life periodHousehold・work place・life space

Acute

RecoveryHospital

Post-Hospital
Late medical・life period : rehab/long-term care

Late medical・life periodHousehold・work place・life space

Squat

Squat

Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives
41

【Prevention and early detection】Ultra small vital sensor Cyvis

Healthcare monitoring on daily basis with Cyvis
Daily accumulation, analysis, and AI processing of various vital data
・Cardiac activity
・brain activity
・body temperature
・Body movements
・Breathing / SpO2 (optional)

Check for arrhythmia and atrial brillation
to prevent myocardial infarction and cerebral infarction
Option to check breathing conditions during sleep for early detection of sleep apnea risk
✅ Developed “Cyvis-2” after trial of “Cyvis-1”✅ “Cyvis-2” submitted medical device application on Apr. 2024 and schedules to commercialize on summer to autumn 2024fi

42

【Prevention and early detection】Ultra small vital sensor Cyvis

Expands remote service that connects households to hospitals and facilities
House

Physical information（つーざー）(User)

User authentication
Device authentication
Data base

Induceimprovementof brain-nerve
and physicalfunction

Remote service to counter the pandemic

t
pp

or

t

Early
detection of
sleep apnea
syndromerisk

Facility(Professional)（つーざー）(User)
Monitor tablet

Mobile tablet

orSupportSupportpp

Su

Physicalinformation

Cyvis

Monitor tablet

Cybernics Device

al
ic on
ys atiPh rmfoinPhysicalinformation

Su

House

(User)
SupportInduceimprovementof brain-nerve
and physicalfunction

Early detectionof risks of
Cerebrovasculardisease, heartdisease, etc.

（つーざー）［Cloud］

SupportMonitor tablet

House

LTE/5G

Physical information

P
in hy
fo si
rm ca
at l
io
n

Cybernics Device【Integrated Cybernics System】

LTE/5GHouse（つーざー）(User)

Monitor tablet

Mobile tablet

Cyvis (Option)

Professional
Staff

43

Cybernics Medical Healthcare System
Prevent, early detect and improve on daily basis (data linkage with Cyberdyne Cloud)Cybernics Medical Healthcare Systemthat prevent, early detect and improve on daily basis
Hospital, Facility, House, Workplaces

Cyberdyne Cloudwith innovative Cybernics System
Cybernics Treatment and monitoringat hospitals

Health care monitoringin daily life

Cloud
Computing

Improve independence to encouragecontinuous social activity

Sleep Apnea Syndrome,
sleep deprivation check

Activity,
sleeping check
Healthcare check and program to improvephysical function at home

Health Care Monitoring in the Workplace

Seamless data linkage between hospitals, facilities, homes, and workplaces with IoH/IoT
44

【Prevention and early detection】Photoacoustic Imaging Device using LED light array

Contrast-free, non-invasive, real-time, high-resolution 3D imaging
LED array method (patent held by CYBERDYNE)

Peripheral level examination,
which could not be done withconventional imaging
equipment, is now possible!
Example of application••
Adopted as the cover of
BioPhotonics, a U.S. industry
journal dealing with biophotonics••

Routine examination and diagnosis of
diabetic foot lesions
Examination of vascular regeneration
status by regenerative medicine
Examination and diagnosis of cancer
Examination of aging skin, etc.

Peripheral vascular and bloodconditions, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device
45

【Prevention/early detection】Acoustic X” photoacoustic imaging system with LED light source
Hospitals with Acoustic X: Various hospitals installed the product for clinical researches

46

C-Startup : Innovation ecosystem to create Cybernics Industry
University andresearch institutions

Cybernics Industry
bio/drug discovery

2020/12 listed

Start-ups andentrepreneurs

Med Tech

C-Startup

Big
Data

2022/6 M&A

regenerative
medicine

2022/12 listed

Cutting-edge
technology

Technical advices
Financial support
Business support

CYBERDYNE
Medical institutions,care facilities, companies,
allied partners

IoH/IoT
Robotics

AI

CEJ Fund (scale of 10 billion)

University, research institute, government
WEF Centre for 4th Industrial Revolution,
Consortium of cutting-edge medicine in the
21st century
Smart city council etc,.

2024.3.31 updated
47

(Ref) Fair value assessment of strategic investment through “C-Startup”
Cumulative investment income 11.4 billion yen vs cumulative investment amount 5.1 billion yen
Realized gain 730 million (5 companies)

Cumulative
investment income
Gain on valuation difference (PL)5.19 billion (12 companies)

5.09 billion

Cumulative investment amount
11.4 billion (32 companies)*Unlisted equity securities are fair valued in accordancewith IFRS 9 "Financial Instruments

Realized loss (PL) 100 million (1 company)
Loss on valuation difference (PL) 1.08 billion(3 companies)

Gain on valuation difference (OCI **)450 million (4 companies)

Realized loss (OCI) 30 million (1 company)

Increase of fair value (21 companies +6.37 billion)

Decrease of fair value (4 companies -1.18 billion)**OCI (Other Comprehensive Income): Income notrecognized in net pro t or loss (PL)
(Reference) Investments in which no valuation
di erences are currently recognized: 6 companies(As of March 31, 2024)

fi

ff

48

Cybernics Medical Innovation Base: Outline
Reinforcing CYBERDYNE’s growth strategy
Accelerate the fusion of bio- and medical-related technologies with AI, robotics, and information technologies

Innovation center based on Cybernics Technology and regenerative medicine/drug discovery
Kingsky Front Tonomachi, Kawasaki
New base with a view to global expansion(5 minutes from Haneda Airport)

Haneda airport

Cybernics medical
innovation baseLife science companies such as C-Startup partners inregenerative medicine and drug discovery move in
New fusion R&D will be promoted!
49

Cybernics Medical Innovation Base: Purpose
1) Combined Cybernics Treatment : Regenerative Medicine and HAL
While "Cybernics Treatment" using the world's rst Wearable Cyborg HAL is becoming a standard
treatment for functional improvement and regeneration of human brain nerves and muscles (HAL isalready available in 20 countries in Europe, the U.S., Asia, etc.), further therapeutic effects are expected
for severe patients by introducing technology at the cellular level and cell-produced substances. The
Group will promote the systemization of Cybernics Treatment at this research facility.

2) Combined Cybernics Treatment : Drug and HAL
After the post-marketing study of "Cybernics Treatment" using the Wearable Cyborg HAL, thecombination of the latest nucleic acid drugs and HAL has begun in actual medical practice, andsynergistic effects from the combined therapy of drugs and HAL are hoped for. CYBERDYNE will
promote the systematization of Cybernics Treatment in cooperation with pharmaceutical companies andthe institutions occupying such research facilities.

3) Integration of medical and bio-based technologies with AI, robotics, and information systems
In addition to deploying the Group's new-generation robotic bioreactor technologies and technologies
that integrate medical/biotechnologies with AI, robotics, and information technologies, the company will
provide research facilities to partner companies (medical/biotechnological companies and start-ups thatcan collaborate with the Company) and others to develop new medical technologies and expand theCompany's business.
fi

50

Disclaimer

This presentation contains forward-looking statements concerning
CYBERDYNE, Inc. and its Group’s future plans, strategies and performance.
Forward-looking statements contained in this presentation are based on
information currently available and on certain assumption redeemed rational at
the time of creation of this presentation. As such, due to various risks anduncertainties, the statements and assumption does not guarantee future
performance, may be considered differently from alternative perspectives andmay differ from the actual result.
Further, this presentation contains statements and information regarding
corporate entities other than those belonging to the CYBERDYNE group, whichhave been complied from various publicly- available sources. CYBERDYNE
does not verify nor guarantees accuracy and appropriateness of those
information.

51